Create knowledge
[?]
|
(rate this)
|
Biotech industry business models have been evolving to product-centered strategies with shorter periods to return on invested capital. 'We're seeing a shift from technology-based to product-based companies. Specifically, we're seeing a shift toward drugs as the driver of value, i.e., clinical compounds as opposed to technologies which focused on the upstream processes of drug discovery. The time from the use of these technologies to getting a drug on the market is so long and that protracted time frame -- 10+ years -- limits what pharmaceutical companies and investors are willing to pay for them,' a senior-level VC points out. 'The focus instead is on nearer term profits. Money invested in ...
 |
mukesh mehta
| Commented
| 3 years ago
|
|
Sir/Madam, We at Zeopane have developed a new and innovative drug-delivery technology called zeolite micro-needles that is superior to the conventional technologies being used currently. Micro-needles are believed to be the drug-delivery mechanism...
|
|
Trends: "Trends in biotechnology " deleted from your view.
|
(rate this)
|
Sir/Madam, We at Zeopane have developed a new and innovative drug-delivery technology called zeolite micro-needles that is superior to the conventional technologies being used currently. Micro-needle...
Answer: "seeking seed funding/ commercialisation of trans dermal dd- microneedle technology" deleted from your view.
Follow me on
